Palisade Bio, Inc.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, with a particular focus on gastrointestinal (GI) disorders. The company's mission is to advance next-generation oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed to improve pharmacology, tolerability, and convenience for patients, thereby transforming proven PDE4 biology into safer and more effective oral therapies. Palisade Bio's headquarters are located in Denver, Colorado.

The company's lead product candidate is PALI-2108, a once-daily oral PDE4 inhibitor prodrug engineered for selective bioactivation within the ileum and colon. This targeted approach aims to treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD), by initiating PDE4 inhibition directly at the sites of disease. PALI-2108 is currently advancing through Phase 2 clinical studies for both UC and Crohn's disease.

In recent news, Palisade Bio reported positive topline data from its Phase 1b clinical study of PALI-2108 in fibrostenotic Crohn's disease in March 2026. The company also announced that an abstract detailing data from PALI-2108 was selected for a poster presentation at Digestive Disease Week (DDW) 2026 in May 2026. The leadership team includes JD Finley as Chief Executive Officer and Mitch Jones, MD, Ph.D. as President & Chief Medical Officer. Palisade Bio operates as a publicly traded entity on the NASDAQ exchange under the ticker symbol PALI.